Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H23NO3 |
Molecular Weight | 313.3908 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O)=CC=C3OCC
InChI
InChIKey=OGDVEMNWJVYAJL-LEPYJNQMSA-N
InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1
Molecular Formula | C19H23NO3 |
Molecular Weight | 313.3908 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
CNS Activity
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.09 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
222 μM × min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
8.5 mg single, oral |
healthy, 10 months n = 1 Health Status: healthy Age Group: 10 months Sex: M Population Size: 1 Sources: |
Other AEs: Sedation... |
1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years n = 10 Health Status: healthy Age Group: 24 years Sex: M Population Size: 10 Sources: |
Other AEs: Dizziness, Drowsiness... Other AEs: Dizziness (7 patients) Sources: Drowsiness (slight, 2 patients) Loose stools (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sedation | grade 5 | 8.5 mg single, oral |
healthy, 10 months n = 1 Health Status: healthy Age Group: 10 months Sex: M Population Size: 1 Sources: |
Loose stools | 1 patient | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years n = 10 Health Status: healthy Age Group: 24 years Sex: M Population Size: 10 Sources: |
Dizziness | 7 patients | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years n = 10 Health Status: healthy Age Group: 24 years Sex: M Population Size: 10 Sources: |
Drowsiness | slight, 2 patients | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years n = 10 Health Status: healthy Age Group: 24 years Sex: M Population Size: 10 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Evidence for the presence of active cytochrome P450 systems in Schistosoma mansoni and Schistosoma haematobium adult worms. | 2002 May 22 |
|
Electrospray LC-MS method with solid-phase extraction for accurate determination of morphine-, codeine-, and ethylmorphine-glucuronides and 6-acetylmorphine in urine. | 2007 Mar |
|
Determining plasma morphine levels using GC-MS after solid phase extraction to monitor drug levels in the postoperative period. | 2008 Jun |
|
Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood. | 2008 May |
|
[Pharmacological treatment of acute cough]. | 2009 May 14 |
|
[The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value]. | 2009 Nov 4-12 |
Sample Use Guides
The recommended dose in adults is 50 mg of codethyline per day, i.e. 10 tablets (1 tablet contains 5 mg of ethylmorphine hydrochloride) per day over several intakes, at a minimum of 4 hours apart. In children the normal dose is 1 tablet per intake, to be renewed after 6 hours if necessary, without exceeding 4 tablets per day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:20:55 GMT 2023
by
admin
on
Fri Dec 15 17:20:55 GMT 2023
|
Record UNII |
RWO67D87EU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS01XA06
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
||
|
DEA NO. |
9190
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
||
|
WHO-ATC |
S01XA06
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
||
|
WHO-VATC |
QR05DA01
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
||
|
WHO-ATC |
R05DA01
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3207
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
D005036
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
4166
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | RxNorm | ||
|
5359271
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
100000078674
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
200-970-7
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
DB01466
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
RWO67D87EU
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
DTXSID1046760
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
CHEMBL1712170
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
ETHYLMORPHINE
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
76-58-4
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
C83704
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | |||
|
m5154
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB13765MIG
Created by
admin on Fri Dec 15 17:20:55 GMT 2023 , Edited by admin on Fri Dec 15 17:20:55 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |